Abre Venous Self-expanding Stent System
Medtronic Vascular, Inc. · Decision date Oct 30, 2026
What did the FDA approve?
FDA records P200026/S020 as a supplement to PMA P200026, with the supplement type “Special (Immediate Track)”. The recorded decision is approval, dated Oct 30, 2026.
FDA approval order statement
which requested approval to add instructions for user disassembly of the device to facilitate manual deployment in the event of partial stent deployment.
- Regulatory pathway
- PMA supplement
- Supplement type
- Special (Immediate Track)
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 30, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P200026/S020
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic Vascular, Inc.
- Product code
- QAN
- Decision code
- APPR
- Decision date
- Oct 30, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stent, iliac vein.
- Applicant
- Medtronic Vascular, Inc.
- Product code
- QAN
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P200026. Subsequent supplements may change the device or its indications.
FDA decision timeline
P200026 · Original PMA
Abre Venous Self-expanding Stent System
P200026/S020 received
Application receipt date recorded by FDA.
P200026/S019 · Related supplement
Abre Venous Self-Expanding Stent System
P200026/S020 · FDA decision
Special (Immediate Track)
Timeline entries are records held by MedtechLedger for P200026. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200026
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Vascular, Inc. | PMA approval | Oct 21, 2020 | FDA | |
Abre Venous Self-Expanding Stent SystemP200026/S019 | Medtronic Vascular, Inc. | PMA supplement | Oct 16, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Vascular, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 3033 Campus Dr., Plymouth, MN, 55441
Sources and methodology
- Original FDA record: P200026/S020
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records